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Abstract
Background: Statin pretreatment has been associated with a decrease in myocardial ischemia markers after
various procedures and cardiovascular events. This study examined the potential beneficial effects of preoperative
atorvastatin treatment among patients undergoing on-pump CABG operation.
Methods: Twenty patients that had received atorvastatin treatment for at least 15 days prior to the operation and
20 patients who had not received any antihyperlipidemic agent prior to surgery were included in this study. CK-MB
and troponin I levels were measured at baseline and 24 hours after the operation. Perioperative variables were also
recorded.
Results: Twenty-four hours after the operation, troponin I and CK-MB levels were significantly lower in the
atorvastatin group: for CK-MB levels, 12.9 ± 4.3 versus 18.7 ± 7.4 ng/ml, p = 0.004; for troponin I levels, 1.7 ± 0.3
versus 2.7 ± 0.7 ng/ml, p < 0.001. In addition, atorvastatin use was associated with a decrease in the duration of
ICU stay.
Conclusions: Preoperative atorvastatin treatment results in significant reductions in the levels of myocardial injury
markers early after on-pump CABG operation, suggesting a reduction in perioperative ischemia in this group of
patients. Further studies are needed to elucidate the mechanisms of these potential benefits of statin pretreatment.
Background
Ambulatory use of 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) reductase inhibitors, or statins, is known
to reduce the risk of cardiovascular events including
death, myocardial infarction, stroke, and renal function,
in addition to their lowering effect on low-density lipo-
protein (LDL) and total cholesterol levels [1]. However,
beneficial effects of statin treatment are not limited to
the patients with hypercholesterolemia. Patients with
normal or low levels of LDL also benefit from long term
statin treatment with lower incidence of cardiovascular
events and reduced need for coronary angioplasty or
coronary surgery [2].
Cardiac isoforms of troponin are specific markers for
myocardial injury. They are highly sensitive indicators
for perioperative myocardial ischemia [3]. Elevated
levels of troponin following revascularization procedures
like percutaneous coronary interventions and coronary
artery bypass grafting (CABG) have been associated
with increased risk of cardiac complications [4]. Even
after a successful percutaneous coronary intervention, 5
to 30% of patients experience elevations of cardiac bio-
markers [5]. Among stabile angina patients that under-
went elective coronary intervention, administration of
atorvastatin for 7 days before the procedure has been
shown to reduce procedure-related myocardial injury
substantially [6].
This study examined the potential beneficial effects of
preoperative atorvastatin treatment given for at least
15 days before on-pump CABG on myocardial injury
indicators, CK-MB and troponin I.
Methods
Patients
Forty patients undergoing elective CABG were included
in this study. Twenty consecutive patients that had
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Sanovel, Istanbul, Turkey) for at least 15 days before
surgery constituted the study group and 20 consecutive
patients that had not received any antihyperlipidemic
agent prior to surgery were included in the control
group. Exclusion criteria were as follows: valvular repair
or any additional cardiac procedure, COPD, left ventri-
cular ejection fraction <30%, emergency operations, and
severe hepatic or renal failure (creatinine > 2 mg/dl).
The study protocol was approved by the Ethics Com-
mittee of Selcuk University Meram Medical Faculty.
Surgical method
All patients underwent primary CABG operation using
standard cardiopulmonary bypass. Fentanyl, midazolam
and pancuronium bromide were used for the induction
of anesthesia. Median sternotomy was used for all
operations and vascular conduits were prepared before
the commencement of cardiopulmonary bypass. Then
300 IU/kg heparin was administered and cardiopulmon-
ary bypass with a roller pump was initiated under mod-
erate hypothermia using standard aortic and two-stage
venous cannula. Cold blood cardioplegia was used in all
patients. Preoperative and postoperative parameters
including durations of aortic cross clamp, respiratory
support, ICU stay, and hospitalization were recorded as
well as pulmonary parameters (arterial blood gas analy-
sis) and the need for inotropic agents. In addition,
serum LDL cholesterol level, erythrocyte sedimentation
rate and leukocyte count were recorded preoperatively.
Measurements of troponin I and CK-MB levels
Blood samples for biochemical analyses were obtained at
t h et i m eo fa n e s t h e s i ai n d u c t i o na n d2 4h o u r sa f t e rt h e
operation from right radial artery. They were kept at
room temperature for 30 minutes before they were cen-
trifuged at 3000 rpm for 5 minutes to separate sera
(Eppendorf centrifugation device 5840; Eppendorf, Ham-
burg, Germany). All blood samples were stored at -80°C
until analysis.
Serum troponin I levels were measured by a commer-
cially available chemiluminescent immunoassay on an
autoanalyser (Immulite Diagnostic Products Co., Los
Angeles, CA, USA). For the quantitative measurements
of serum CK-MB levels, a commercially available chemi-
luminescent enzyme labeled immunometric assay was
used on an autoanalyser (Immulite Diagnostic Products
Co., Los Angeles, CA, USA).
Statistical analysis
Statistical analysis was performed using SPSS version
15.0 software (SPSS Inc., Chicago, IL, USA) for Win-
dows. Continuous variables were expressed as mean ±
SD or median and interquartile range. Differences
between groups were tested using Student t test or
Mann-Whitney U-test. Categorical data were compared
using Chi-square test or Fisher’s exact test. A p value <
0.05 was considered as an indication of statistical
significance.
Results
Demographical, clinical and operative data of the two
groups are presented in Table 1. The two groups did
not differ with regard to age, gender, weight, preopera-
tive laboratory findings, cardiovascular risk factors, and
perioperative variables. No statistically significant differ-
ence was found in LDL levels between the two groups.
Transient atrial fibrillation developed in one patient in
each of the groups (p = 1.00) and no other arrhythmia
was observed in any of the subjects.
Although troponin I and CK-MB levels were similar at
baseline (Table 1), 24 hours after the operation both
levels were significantly lower in the group that had
received atorvastatin compared to controls: for CK-MB
levels, 12.9 ± 4.3 versus 18.7 ± 7.4 ng/ml, p = 0.004; for
troponin I levels, 1.7 ± 0.3 versus 2.7 ± 0.7 ng/ml, p <
0.001 (Figure 1). Groups did not differ with regard to
postoperative variables, except for a shorter duration of
ICU stay among patients that had received atorvastatin
pretreatment (p = 0.046) (Table 1). Early mortality was
not observed in either of the groups.
Discussion
The main finding of this study is the decreased early
postoperative levels of myocardial injury indicators in
association with the use of atorvastatin for a certain per-
iod prior to the CABG operation. In addition, atorvasta-
tin treatment was associated with shorter duration of
ICU stay. Preoperative statin use seems to have a role in
decreasing CABG associated morbidity through attenua-
tion of cardiopulmonary bypass-related acute inflamma-
tory reaction and improvement of endothelial function
owing to its antioxidant activities.
Beneficial effects of statin pretreatment have already
been demonstrated in a number of studies on patients
undergoing cardiac interventions. In a randomized
study, pretreatment with atorvastatin before angioplasty
has been shown to decrease the incidence of myocardial
injury when compared to placebo. Atorvastatin pretreat-
ment was associated with a significant reduction in the
release of all myocardial injury indicators like myoglo-
bin, troponin I, and CK-MB following the percutaneous
procedure [5]. In another study with a design similar to
this study, except for the use of a different statin and
placebo, Mannacio et al. administered one-week 20 mg/
day rosuvastatin treatment or placebo before CABG
operation and found significantly lower levels of tropo-
nin I, myoglobin and creatinine kinase in association
with rosuvastatin treatment compared to placebo,
Ege et al. Journal of Cardiothoracic Surgery 2010, 5:60
http://www.cardiothoracicsurgery.org/content/5/1/60
Page 2 of 6Table 1 Demographical, clinical and operative data of the patients (n = 40)
Characteristics Atorvastatin pretreatment n = 20 No atorvastatin pretreatment n = 20 P for difference
Demographical and baseline clinical data
Age, y 58.8 (8)* 61 (11) * 0.44
Weight, kg (mean ± SD) 83.1 ± 2.4 83.6 ± 2.3 0.88
Male to female ratio 16/4 15/5 1.0
Diabetes, n (%) 7 (35%) 9 (45%) 0.51
Hypertension, n (%) 6 (30%) 6 (30%) 1.0
Ejection fraction, % 40 (8.5)* 40 (13.5)* 0.26
LDL, mg/dl (mean ± SD) 100.7 ± 9.20 97.5 ± 6.0 0.20
CK-MB, ng/ml 2 (1.5)* 1.85 (1.6)* 0.79
Troponin I, ng/ml 0.2 (0.2)* 0.2 (2.6)* 0.30
Erythrocyte sedimentation rate, mm/h (mean ± SD) 18.9 ± 7.3 18.3 ± 6.8 0.77
Preoperative creatinine level, mg/dl 1.0 (0.3)* 1.0 (0.28)* 0.47
Intraoperative and postoperative parameters
Duration of aortic cross clamp, min (mean ± SD) 63.5 ± 20.8 65.3 ± 20.9 0.79
Duration of CPB, min (mean ± SD) 103.2 ± 30.7 98.3 ± 26.3 0.58
ICU stay time, d 2.0 (1.0)* 3.5 (2.5)* 0.046
Duration of intubation, h 8.0 (5.5)* 7.0 (10.25)* 0.968
PO2, mmHg 93.8 (22.93)* 86.0 (20.99)* 0.26
CO2, mmHg 36.45 (3.64)* 37.8 (3.67)* 0.25
SaO2, % 97.0 (3.75)* 95.4 (3.25)* 0.686
Inotropic support, n (%) 10 (50%) 13 (65%) 0.33
Duration of hospitalization, d 7.0 (1.0)* 8.0 (1.75)* 0.25
Number of bypasses, n 3.0 (1.75)* 3.0 (1.0)* 0.14
Postoperative creatinine level, mg/dl 1.1 (0.48)* 0.95(0.6)* 0.37
Need for blood and blood products, U 3.5 (1.0)* 4.0 (1.0)* 0.97
Postoperative EF, % 40 (10.25)* 42 (10.25)* 0.94
Total postoperative bleeding, ml 762.5 (298.7)* 775 (267.5)* 0.82
* median (interquartile range).
Figure 1 CK-MB (A) and troponin I (B) and levels of the patients 24 hours after CABG operation.
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[7]. Similar to the findings of these previous studies, this
study found lower levels of troponin I and CK-MB in
association with preoperative atorvastatin use among
patients undergoing CABG, providing further evidence
for the benefits of statin administration for a period
prior to coronary interventions.
Besides, several studies confirmed the clinical benefit
of statins in terms of reduced mortality and morbidity.
Preoperative statin treatment was shown to decrease
30-day mortality and acute MI risks significantly after
CABG [8]. Likewise, in the retrospective study by
Magovern et al. on 2377 patients, decreased operative
mortality rates was evident among high-risk patients in
association with preoperative statin treatment [9].
Long-term benefits of statin treatment have also been
shown after CABG operation. Aggressive lipid lowering
therapy has been shown to slow down progression of
obstructive changes in saphenous vein grafts and
reduce the need for a new revascularization procedure
[10]. Significantly lower 30-day MI and mortality rates
were observed among acute coronary syndrome
patients if they were on statins at the time of the event
[11]. Although not the subject of this study, current
evidence suggest that ischemia preventing effect of
atorvastatin during perioperative period may well
translate into or contribute to longer term benefits
with continued use.
Based on this growing evidence, initiation of statin
treatment at the time of revascularization planning has
become a widely accepted practice. Although the opti-
mal duration of pretreatment to obtain clinical benefit is
not yet clear, experimental data suggest that 14 days of
pretreatment would have substantial favorable effect on
inflammation and endothelial function [12]. Therefore,
patients that had received at least 14 days of atorvastatin
treatment were included in the study group of the pre-
sent study.
Cardiac isoforms of troponin are specific myocardial
injury markers indicating the level of perioperative myo-
cardial ischemia. Moderate elevations of troponin I and
T after CABG operation suggests minimal and reversible
injury [3]. Troponin I is more sensitive than CK-MB
and troponin T for the assessment of myocardial injury
[13]. Although clinical implications of troponin I release
after coronary interventions have not been widely stu-
died, observational studies have found a correlation
between troponin I levels and untoward events during
hospitalization. In contrast, normal troponin I levels
after coronary procedures almost eliminate the risk for
in-hospital complications [14]. Thus, the lower troponin
I levels among the atorvastatin group compared to con-
trols found in this study may translate into lower post-
operative complication rates, both in terms of mortality
and morbidity, which warrants investigation in long
term randomized controlled trials.
A s y m p t o m a t i cm y o c a r d i a li n j u r ya sa s s e s s e db ye l e v a -
tions of CK-MB levels is quite frequent after coronary
interventions with a prevalence ranging between 10 to
40% of the cases [15]. Only a small increase in myocar-
dial necrosis indicators without any impairment of car-
diac function or ECG change may be seen in most of
the patients [16]. In this study, the levels of myocardial
injury indicators troponin I and CK-MB were signifi-
cantly lower at 24 hours after CABG procedure in
patients that received preoperative atorvastatin
treatment.
In the study by Kourliouros et al., statin treatment was
associated with a lower incidence of atrial fibrillation
and a shorter duration of hospitalization after cardiac
surgery [17]. However, they did not find any change in
the duration of ICU stay. In contrast, this study found a
shorter duration of ICU stay associated with statin treat-
ment and no difference in terms of postoperative atrial
fibrillation and duration of hospitalization. Significant
reduction in myocardial damage as demonstrated by low
levels of indicators might indirectly contribute to the
reduced need for ICU support. However, it is of note to
emphasize that many factors may prolong ICU stay, and
this study found only a marginal difference between the
two groups in terms of duration of hospital stay (p =
0.046). Future studies with larger sample sizes allowing
multivariate analysis to adjust for multiple confounding
factors would provide robust evidence on potential
effect of atorvastatin treatment on the duration of ICU
stay or hospitalization. Increasing the number of
patients would also probably result in sufficient number
of incidences related to postoperative ischemia that
would translate into prolonged ICU and/or hospital stay.
Thus, until then, such a possible indirect effect of ator-
vastatin treatment should be interpreted cautiously.
Experimental and clinical studies suggest that benefi-
cial effects of statins may be beyond their cholesterol
lowering effect [18,19]. These pleiotropic effects inde-
pendent of cholesterol lowering include the improve-
ment of endothelial function, NO related antioxidant
activity, and inhibition of inflammatory response, vaso-
constriction, thrombosis, and thrombocyte aggregation
[20]. Several studies demonstrated a decrease in sys-
temic inflammatory response with statin treatment dur-
ing on-pump CABG operations. Chello et al.
demonstrated a decrease in P-selectin release from the
endothelium and CD11b release from neutrophils after
CABG with statin treatment, which in turn inhibits the
adhesion of activated neutrophils to the vascular
endothelium [21]. In addition, neutrophil apoptosis was
increased and the levels of circulating adhesion mole-
cules ICAM-1 and ELAM-1 were decreased. They also
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endothelium was evident even at doses ineffective for
the reduction of cholesteroll e v e l s[ 2 1 ] .I nap r e v i o u s
study, we found a decrease in cardiopulmonary bypass-
related systemic inflammatory response and endothelial
function improvement in association with preoperative
atorvastatin treatment in patients undergoing elective
CABG operation [22]. Using experimental ischemia and
reperfusion model, preoperative statin treatment have
been shown to augment cardioprotective effects, signifi-
cantly reduce myocardial infarct area and preserve car-
diac contractile function and coronary perfusion [23].
Recent studies showed that statins affect important fac-
tors taking part in the pathogenesis of acute coronary
syndrome including endothelial NO, endothelin, metal-
loproteinases, plasminogen activating factor, tissue plas-
minogen activator, and free radical production. The
molecular basis of these statin effects beyond cholesterol
lowering is the inhibition of isoprenoid intermediate
pathways of cholesterol metabolism [24]. Above men-
tioned anti-inflammatory and antioxidative mechanisms,
and improved endothelial function all seem to be
responsible for and contributing to the reduced ischemia
associated with perioperative atorvastatin use, among
patients undergoing CABG or other coronary
interventions.
This study has several limitations. First, this study
evaluated troponin I and CK-MB levels before and at
24 hours after the operation. If serial blood samples had
been obtained instead of a single measurement after the
operation, the course of myocardial ischemia under
atorvastatin treatment could be evaluated with reference
to the control group. Second, our sample size is rela-
tively small. Greater number of enrolled patients would
be associated with a reduction of a potential statistical
type II error, particularly for parameters other than mar-
kers and ICU stay time, and multivariate analysis allow-
ing adjustment for multiple factors would be possible.
Finally, a randomized controlled design would provide
robust evidence.
Conclusions
In conclusion, findings of this study suggest that preo-
perative atorvastatin treatment results in a significant
reduction in the levels of myocardial injury indicators
among patients undergoing on-pump CABG operation,
thereby providing a benefit in terms of reducing perio-
perative ischemia in this group of patients. This seems
to be due to a reduction in acute inflammatory reaction
and cardioprotective effects of statins through NO
related antioxidant activity and improvement of
endothelial function. Larger randomized controlled stu-
dies with robust design allowing adjustment for con-
founding variables would provide further insight into
the benefits provided by statin pretreatment and their
mechanism.
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